Hebei Changshan Biochem Pharma (300255) — Cash Flow Reinvestment Rate
Hebei Changshan Biochem Pharma (300255) has a Cash Flow Reinvestment Rate of 0.53x as of June 2025, reinvesting CN¥37.29 Million (capex CN¥18.63 Million plus investments CN¥-18.66 Million) from operating cash flow of CN¥70.22 Million. See free cash flow generation of Hebei Changshan Biochem Pharma to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Hebei Changshan Biochem Pharma Cash Flow Reinvestment Rate (2009–2024)
Historical reinvestment intensity for Hebei Changshan Biochem Pharma across 10 annual periods. For the full cash flow conversion analysis, see Hebei Changshan Biochem Pharma cash flow conversion.
Annual Cash Flow Reinvestment Rate for Hebei Changshan Biochem Pharma (2009–2024)
Year-by-year capital reinvestment analysis for Hebei Changshan Biochem Pharma. See 300255 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 8.42x | CN¥473.35 Million | CN¥56.22 Million | CN¥239.59 Million | ▼ -40.6% |
| 2023 | 14.18x | CN¥478.17 Million | CN¥33.73 Million | CN¥239.32 Million | ▼ -94.9% |
| 2022 | 275.97x | CN¥862.55 Million | CN¥3.13 Million | CN¥431.22 Million | ▲ +28.8% |
| 2021 | 214.31x | CN¥615.39 Million | CN¥2.87 Million | CN¥308.08 Million | ▲ +26150.7% |
| 2018 | 0.82x | CN¥239.05 Million | CN¥292.81 Million | CN¥234.85 Million | ▼ -46.2% |
| 2017 | 1.52x | CN¥246.30 Million | CN¥162.28 Million | CN¥158.30 Million | ▼ -39.5% |
| 2016 | 2.51x | CN¥431.24 Million | CN¥171.96 Million | CN¥96.52 Million | ▲ +40.5% |
| 2011 | 1.79x | CN¥30.43 Million | CN¥17.04 Million | CN¥30.43 Million | ▲ +39.0% |
| 2010 | 1.28x | CN¥37.56 Million | CN¥29.25 Million | CN¥37.56 Million | ▲ +29.3% |
| 2009 | 0.99x | CN¥24.05 Million | CN¥24.21 Million | CN¥24.05 Million | — |